25 XP   0   0   10

Hikma Pharmaceuticals PLC
Buy, Hold or Sell?

Let's analyse Hikma together

PenkeI guess you are interested in Hikma Pharmaceuticals PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hikma Pharmaceuticals PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hikma Pharmaceuticals PLC

I send you an email if I find something interesting about Hikma Pharmaceuticals PLC.

Quick analysis of Hikma (30 sec.)










What can you expect buying and holding a share of Hikma? (30 sec.)

How much money do you get?

How much money do you get?
p2.46
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
p797.50
Expected worth in 1 year
p921.86
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
p322.20
Return On Investment
18.0%

For what price can you sell your share?

Current Price per Share
p1,789.00
Expected price per share
p1,678 - p2,103
How sure are you?
50%

1. Valuation of Hikma (5 min.)




Live pricePrice per Share (EOD)

p1,789.00

Intrinsic Value Per Share

p920.40 - p2,094.83

Total Value Per Share

p1,717.90 - p2,892.33

2. Growth of Hikma (5 min.)




Is Hikma growing?

Current yearPrevious yearGrowGrow %
How rich?$2.2b$2.1b$60.9m2.8%

How much money is Hikma making?

Current yearPrevious yearGrowGrow %
Making money$189.6m$187.6m$1.9m1.1%
Net Profit Margin6.6%7.5%--

How much money comes from the company's main activities?

3. Financial Health of Hikma (5 min.)




What can you expect buying and holding a share of Hikma? (5 min.)

Welcome investor! Hikma's management wants to use your money to grow the business. In return you get a share of Hikma.

What can you expect buying and holding a share of Hikma?

First you should know what it really means to hold a share of Hikma. And how you can make/lose money.

Speculation

The Price per Share of Hikma is p1,789. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hikma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hikma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p797.50. Based on the TTM, the Book Value Change Per Share is p31.09 per quarter. Based on the YOY, the Book Value Change Per Share is p-83.60 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p49.46 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hikma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps0.850.0%0.850.0%0.830.0%1.460.1%0.800.0%
Usd Book Value Change Per Share0.390.0%0.390.0%-1.04-0.1%0.580.0%0.530.0%
Usd Dividend Per Share0.620.0%0.620.0%0.550.0%0.510.0%0.410.0%
Usd Total Gains Per Share1.000.1%1.000.1%-0.480.0%1.090.1%0.930.1%
Usd Price Per Share22.25-22.25-19.30-25.04-23.74-
Price to Earnings Ratio26.08-26.08-23.14-18.85-18.91-
Price-to-Total Gains Ratio22.21-22.21--39.80-10.14-12.79-
Price to Book Ratio2.24-2.24-2.03-2.64-3.00-
Price-to-Total Gains Ratio22.21-22.21--39.80-10.14-12.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share22.248004
Number of shares44
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.620.51
Usd Book Value Change Per Share0.390.58
Usd Total Gains Per Share1.001.09
Gains per Quarter (44 shares)44.0848.02
Gains per Year (44 shares)176.31192.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11086816689103182
2217136342179205374
3325204518268308566
4433272694358411758
5541340870447513950
665040810465366161142
775847612226267191334
886654413987158211526
997461215748059241718
101083681175089410271910

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%21.01.00.095.5%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%20.02.00.090.9%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.02.090.9%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%20.02.00.090.9%

Fundamentals of Hikma

About Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-04-10 06:09:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Hikma Pharmaceuticals PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hikma earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Hikma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 6.6% means that 0.07 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 6.6%. The company is making a profit. +1
  • The TTM is 6.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.6%TTM6.6%0.0%
TTM6.6%YOY7.5%-0.9%
TTM6.6%5Y14.2%-7.6%
5Y14.2%10Y8.5%+5.7%
1.1.2. Return on Assets

Shows how efficient Hikma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hikma to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.1% Return on Assets means that Hikma generated 0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 4.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.1%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.1%TTM4.1%0.0%
TTM4.1%YOY4.2%-0.1%
TTM4.1%5Y8.1%-4.1%
5Y8.1%10Y4.9%+3.2%
1.1.3. Return on Equity

Shows how efficient Hikma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hikma to the Drug Manufacturers - Specialty & Generic industry mean.
  • 8.6% Return on Equity means Hikma generated 0.09 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 8.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 8.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ8.6%TTM8.6%0.0%
TTM8.6%YOY8.8%-0.2%
TTM8.6%5Y15.6%-6.9%
5Y15.6%10Y8.7%+6.8%

1.2. Operating Efficiency of Hikma Pharmaceuticals PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hikma is operating .

  • Measures how much profit Hikma makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hikma to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 21.3% means the company generated 0.21  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 21.3%. The company is operating efficient. +1
  • The TTM is 21.3%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ21.3%TTM21.3%0.0%
TTM21.3%YOY23.5%-2.2%
TTM21.3%5Y23.0%-1.7%
5Y23.0%10Y15.8%+7.2%
1.2.2. Operating Ratio

Measures how efficient Hikma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.79 means that the operating costs are 0.79 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 0.790. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.790. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.790TTM0.7900.000
TTM0.790YOY0.885-0.096
TTM0.7905Y0.794-0.004
5Y0.79410Y0.787+0.006

1.3. Liquidity of Hikma Pharmaceuticals PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hikma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.57 means the company has 1.57 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 1.568. The company is able to pay all its short-term debts. +1
  • The TTM is 1.568. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.568TTM1.5680.000
TTM1.568YOY1.856-0.288
TTM1.5685Y1.722-0.154
5Y1.72210Y1.753-0.031
1.3.2. Quick Ratio

Measures if Hikma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hikma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.81 means the company can pay off 0.81 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 0.813. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.813. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.813TTM0.8130.000
TTM0.813YOY1.013-0.200
TTM0.8135Y0.985-0.172
5Y0.98510Y0.961+0.024

1.4. Solvency of Hikma Pharmaceuticals PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hikma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hikma to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.53 means that Hikma assets are financed with 52.8% credit (debt) and the remaining percentage (100% - 52.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 0.528. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.528. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.528TTM0.5280.000
TTM0.528YOY0.520+0.008
TTM0.5285Y0.484+0.044
5Y0.48410Y0.487-0.003
1.4.2. Debt to Equity Ratio

Measures if Hikma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hikma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 112.4% means that company has 1.12 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 1.124. The company is able to pay all its debts with equity. +1
  • The TTM is 1.124. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.124TTM1.1240.000
TTM1.124YOY1.088+0.036
TTM1.1245Y0.954+0.170
5Y0.95410Y0.968-0.014

2. Market Valuation of Hikma Pharmaceuticals PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Hikma generates.

  • Above 15 is considered overpriced but always compare Hikma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 26.08 means the investor is paying 26.08 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hikma Pharmaceuticals PLC:

  • The EOD is 26.081. Based on the earnings, the company is overpriced. -1
  • The MRQ is 26.081. Based on the earnings, the company is overpriced. -1
  • The TTM is 26.081. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD26.081MRQ26.0810.000
MRQ26.081TTM26.0810.000
TTM26.081YOY23.137+2.944
TTM26.0815Y18.847+7.234
5Y18.84710Y18.905-0.058
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hikma Pharmaceuticals PLC:

  • The EOD is 12.266. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 12.266. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 12.266. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD12.266MRQ12.2660.000
MRQ12.266TTM12.2660.000
TTM12.266YOY14.262-1.996
TTM12.2665Y18.890-6.624
5Y18.89010Y22.304-3.414
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hikma is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Hikma Pharmaceuticals PLC:

  • The EOD is 2.243. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.243. Based on the equity, the company is underpriced. +1
  • The TTM is 2.243. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.243MRQ2.2430.000
MRQ2.243TTM2.2430.000
TTM2.243YOY2.025+0.218
TTM2.2435Y2.637-0.394
5Y2.63710Y2.995-0.358
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hikma Pharmaceuticals PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--31.09131.0910%-83.597+369%46.908-34%42.339-27%
Book Value Per Share--797.498797.4980%766.406+4%768.362+4%667.004+20%
Current Ratio--1.5681.5680%1.856-16%1.722-9%1.753-11%
Debt To Asset Ratio--0.5280.5280%0.520+2%0.484+9%0.487+8%
Debt To Equity Ratio--1.1241.1240%1.088+3%0.954+18%0.968+16%
Dividend Per Share--49.46049.4600%44.600+11%40.844+21%32.787+51%
Eps--68.59468.5940%67.078+2%117.334-42%64.434+6%
Free Cash Flow Per Share--145.853145.8530%108.824+34%114.208+28%99.411+47%
Free Cash Flow To Equity Per Share--24.18824.1880%88.130-73%35.614-32%48.086-50%
Gross Profit Margin--1.0001.0000%1.0000%0.777+29%0.595+68%
Intrinsic Value_10Y_max--2094.834--------
Intrinsic Value_10Y_min--920.399--------
Intrinsic Value_1Y_max--149.028--------
Intrinsic Value_1Y_min--98.601--------
Intrinsic Value_3Y_max--494.173--------
Intrinsic Value_3Y_min--292.493--------
Intrinsic Value_5Y_max--895.267--------
Intrinsic Value_5Y_min--480.775--------
Market Cap396952250688.0000%397817629346.000397817629346.0000%349200000000.000+14%469428325869.200-15%442833739510.600-10%
Net Profit Margin--0.0660.0660%0.075-12%0.142-53%0.085-22%
Operating Margin--0.2130.2130%0.235-9%0.230-7%0.158+34%
Operating Ratio--0.7900.7900%0.885-11%0.794-1%0.787+0%
Pb Ratio2.2430%2.2432.2430%2.025+11%2.637-15%2.995-25%
Pe Ratio26.0810%26.08126.0810%23.137+13%18.847+38%18.905+38%
Price Per Share1789.0000%1789.0001789.0000%1552.000+15%2013.800-11%1909.200-6%
Price To Free Cash Flow Ratio12.2660%12.26612.2660%14.262-14%18.890-35%22.304-45%
Price To Total Gains Ratio22.2090%22.20922.2090%-39.798+279%10.142+119%12.787+74%
Quick Ratio--0.8130.8130%1.013-20%0.985-17%0.961-15%
Return On Assets--0.0410.0410%0.042-3%0.081-50%0.049-18%
Return On Equity--0.0860.0860%0.088-2%0.156-44%0.087-1%
Total Gains Per Share--80.55180.5510%-38.997+148%87.752-8%75.126+7%
Usd Book Value--2205381834.7202205381834.7200%2144481747.840+3%2216563490.016-1%1927337995.440+14%
Usd Book Value Change Per Share--0.3870.3870%-1.040+369%0.583-34%0.527-27%
Usd Book Value Per Share--9.9189.9180%9.531+4%9.555+4%8.295+20%
Usd Dividend Per Share--0.6150.6150%0.555+11%0.508+21%0.408+51%
Usd Eps--0.8530.8530%0.834+2%1.459-42%0.801+6%
Usd Free Cash Flow--403338280.320403338280.3200%304500434.400+32%328261451.904+23%286130572.128+41%
Usd Free Cash Flow Per Share--1.8141.8140%1.353+34%1.420+28%1.236+47%
Usd Free Cash Flow To Equity Per Share--0.3010.3010%1.096-73%0.443-32%0.598-50%
Usd Market Cap4936498189.5560%4947260038.5474947260038.5470%4342651200.000+14%5837810660.509-15%5507080384.554-10%
Usd Price Per Share22.2480%22.24822.2480%19.301+15%25.044-11%23.743-6%
Usd Profit--189688795.200189688795.2000%187692071.040+1%342637865.856-45%183698622.720+3%
Usd Revenue--2870290980.0002870290980.0000%2512877355.360+14%2494507493.088+15%2134298454.624+34%
Usd Total Gains Per Share--1.0021.0020%-0.485+148%1.091-8%0.934+7%
 EOD+0 -2MRQTTM+0 -0YOY+22 -135Y+14 -2210Y+20 -16

3.2. Fundamental Score

Let's check the fundamental score of Hikma Pharmaceuticals PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1526.081
Price to Book Ratio (EOD)Between0-12.243
Net Profit Margin (MRQ)Greater than00.066
Operating Margin (MRQ)Greater than00.213
Quick Ratio (MRQ)Greater than10.813
Current Ratio (MRQ)Greater than11.568
Debt to Asset Ratio (MRQ)Less than10.528
Debt to Equity Ratio (MRQ)Less than11.124
Return on Equity (MRQ)Greater than0.150.086
Return on Assets (MRQ)Greater than0.050.041
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Hikma Pharmaceuticals PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.943
Ma 20Greater thanMa 501,846.975
Ma 50Greater thanMa 1001,875.418
Ma 100Greater thanMa 2001,833.697
OpenGreater thanClose1,792.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets4,680,000
Total Liabilities2,471,000
Total Stockholder Equity2,198,000
 As reported
Total Liabilities 2,471,000
Total Stockholder Equity+ 2,198,000
Total Assets = 4,680,000

Assets

Total Assets4,680,000
Total Current Assets2,100,000
Long-term Assets2,580,000
Total Current Assets
Cash And Cash Equivalents 205,000
Net Receivables 884,000
Inventory 891,000
Other Current Assets 120,000
Total Current Assets  (as reported)2,100,000
Total Current Assets  (calculated)2,100,000
+/-0
Long-term Assets
Property Plant Equipment 1,141,000
Goodwill 388,000
Intangible Assets 712,000
Long-term Assets Other 113,000
Long-term Assets  (as reported)2,580,000
Long-term Assets  (calculated)2,354,000
+/- 226,000

Liabilities & Shareholders' Equity

Total Current Liabilities1,339,000
Long-term Liabilities1,132,000
Total Stockholder Equity2,198,000
Total Current Liabilities
Short-term Debt 161,000
Short Long Term Debt 150,000
Accounts payable 568,000
Other Current Liabilities 384,000
Total Current Liabilities  (as reported)1,339,000
Total Current Liabilities  (calculated)1,263,000
+/- 76,000
Long-term Liabilities
Long term Debt 975,000
Capital Lease Obligations 66,000
Long-term Liabilities Other 70,000
Long-term Liabilities  (as reported)1,132,000
Long-term Liabilities  (calculated)1,111,000
+/- 21,000
Total Stockholder Equity
Common Stock40,000
Retained Earnings 2,158,000
Total Stockholder Equity (as reported)2,198,000
Total Stockholder Equity (calculated)2,198,000
+/-0
Other
Capital Stock40,000
Cash and Short Term Investments 205,000
Common Stock Shares Outstanding 222,369
Current Deferred Revenue226,000
Liabilities and Stockholders Equity 4,680,000
Net Debt 986,000
Net Invested Capital 3,323,000
Net Working Capital 761,000
Property Plant and Equipment Gross 2,156,000
Short Long Term Debt Total 1,191,000



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-06-302022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-31
> Total Assets 
94,863
117,863
246,479
397,959
488,353
894,043
966,459
1,022,723
1,099,823
1,575,638
1,730,112
1,929,000
2,251,000
2,597,000
4,363,000
3,388,000
3,497,000
3,930,000
4,135,000
4,372,000
4,471,000
0
4,680,000
4,680,00004,471,0004,372,0004,135,0003,930,0003,497,0003,388,0004,363,0002,597,0002,251,0001,929,0001,730,1121,575,6381,099,8231,022,723966,459894,043488,353397,959246,479117,86394,863
   > Total Current Assets 
64,368
80,354
160,476
284,940
299,831
366,200
415,205
456,600
478,116
659,885
781,967
897,000
1,013,000
1,360,000
1,448,000
1,574,000
1,668,000
1,848,000
1,922,000
2,094,000
1,999,000
0
2,100,000
2,100,00001,999,0002,094,0001,922,0001,848,0001,668,0001,574,0001,448,0001,360,0001,013,000897,000781,967659,885478,116456,600415,205366,200299,831284,940160,47680,35464,368
       Cash And Cash Equivalents 
12,095
22,021
13,872
141,078
91,564
34,532
63,545
67,997
66,292
97,310
176,510
168,000
280,000
553,000
155,000
227,000
276,000
442,000
323,000
426,000
270,000
0
205,000
205,0000270,000426,000323,000442,000276,000227,000155,000553,000280,000168,000176,51097,31066,29267,99763,54534,53291,564141,07813,87222,02112,095
       Short-term Investments 
0
0
35,234
5,120
5,337
5,628
819
2,334
3,573
2,595
1,756
7,000
8,000
20,000
20,000
22,000
21,000
23,000
24,000
24,000
22,000
0
0
0022,00024,00024,00023,00021,00022,00020,00020,0008,0007,0001,7562,5953,5732,3348195,6285,3375,12035,23400
       Net Receivables 
0
0
63,849
83,329
115,894
178,139
179,372
208,868
204,440
299,264
304,082
400,000
406,000
450,000
715,000
716,000
745,000
799,000
662,000
781,000
777,000
0
884,000
884,0000777,000781,000662,000799,000745,000716,000715,000450,000406,000400,000304,082299,264204,440208,868179,372178,139115,89483,32963,84900
       Inventory 
21,905
27,257
44,365
58,017
83,719
140,411
154,757
160,510
182,193
239,260
272,231
276,000
273,000
251,000
459,000
488,000
528,000
568,000
757,000
695,000
776,000
0
891,000
891,0000776,000695,000757,000568,000528,000488,000459,000251,000273,000276,000272,231239,260182,193160,510154,757140,41183,71958,01744,36527,25721,905
   > Long-term Assets 
30,495
37,509
86,003
113,019
188,522
527,842
551,254
566,124
621,707
915,753
948,145
1,032,000
1,238,000
1,237,000
2,915,000
1,814,000
1,829,000
2,082,000
1,978,000
2,084,000
2,257,000
0
2,580,000
2,580,00002,257,0002,084,0001,978,0002,082,0001,829,0001,814,0002,915,0001,237,0001,238,0001,032,000948,145915,753621,707566,124551,254527,842188,522113,01986,00337,50930,495
       Property Plant Equipment 
29,740
36,895
71,471
91,209
156,845
243,901
271,650
283,371
317,463
421,357
419,943
443,000
514,000
507,000
969,000
828,000
870,000
962,000
1,068,000
1,146,000
1,081,000
0
1,141,000
1,141,00001,081,0001,146,0001,068,000962,000870,000828,000969,000507,000514,000443,000419,943421,357317,463283,371271,650243,901156,84591,20971,47136,89529,740
       Goodwill 
0
0
812
1,787
8,924
148,083
154,587
155,458
177,077
269,405
267,022
278,000
314,000
292,000
682,000
282,000
279,000
282,000
289,000
285,000
389,000
0
388,000
388,0000389,000285,000289,000282,000279,000282,000682,000292,000314,000278,000267,022269,405177,077155,458154,587148,0838,9241,78781200
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
24,000
18,000
9,000
14,000
22,000
38,000
43,000
0
0
0
0
0
0000043,00038,00022,00014,0009,00018,00024,00000000000000
       Intangible Assets 
503
416
5,033
7,734
15,016
259,841
258,228
255,697
269,120
408,804
166,027
169,000
288,000
315,000
1,037,000
503,000
487,000
552,000
587,000
607,000
735,000
0
712,000
712,0000735,000607,000587,000552,000487,000503,0001,037,000315,000288,000169,000166,027408,804269,120255,697258,228259,84115,0167,7345,033416503
       Other Assets 
0
0
5,781
4,321
6,194
19,714
18,436
20,010
33,288
46,072
55,772
118,000
104,000
114,000
213,000
179,000
155,000
257,000
235,000
194,000
215,000
0
0
00215,000194,000235,000257,000155,000179,000213,000114,000104,000118,00055,77246,07233,28820,01018,43619,7146,1944,3215,78100
> Total Liabilities 
46,835
57,391
101,303
110,479
138,554
469,382
357,465
339,467
349,521
777,005
882,262
895,000
1,035,000
1,245,000
1,952,000
1,860,000
1,800,000
1,801,000
1,987,000
1,905,000
2,323,000
0
2,471,000
2,471,00002,323,0001,905,0001,987,0001,801,0001,800,0001,860,0001,952,0001,245,0001,035,000895,000882,262777,005349,521339,467357,465469,382138,554110,479101,30357,39146,835
   > Total Current Liabilities 
36,627
37,998
73,229
76,700
106,727
394,035
228,434
204,444
252,624
390,581
466,954
586,000
841,000
592,000
918,000
797,000
893,000
1,471,000
1,028,000
1,016,000
1,077,000
0
1,339,000
1,339,00001,077,0001,016,0001,028,0001,471,000893,000797,000918,000592,000841,000586,000466,954390,581252,624204,444228,434394,035106,72776,70073,22937,99836,627
       Short-term Debt 
0
0
35,234
0
0
0
819
2,334
3,573
2,595
0
443,000
64,000
45,000
20,000
87,000
75,000
578,000
168,000
121,000
148,000
0
161,000
161,0000148,000121,000168,000578,00075,00087,00020,00045,00064,000443,00002,5953,5732,33481900035,23400
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
443,000
64,000
45,000
117,000
86,000
74,000
569,000
158,000
112,000
139,000
0
150,000
150,0000139,000112,000158,000569,00074,00086,000117,00045,00064,000443,00000000000000
       Accounts payable 
0
0
16,612
26,738
32,331
49,143
42,632
57,307
74,936
97,756
110,600
120,000
129,000
139,000
172,000
218,000
263,000
473,000
279,000
262,000
291,000
0
568,000
568,0000291,000262,000279,000473,000263,000218,000172,000139,000129,000120,000110,60097,75674,93657,30742,63249,14332,33126,73816,61200
       Other Current Liabilities 
0
0
20,437
32,851
37,565
64,781
67,281
84,992
94,421
136,674
159,995
306,000
318,000
182,000
390,000
492,000
490,000
315,000
749,000
754,000
786,000
0
384,000
384,0000786,000754,000749,000315,000490,000492,000390,000182,000318,000306,000159,995136,67494,42184,99267,28164,78137,56532,85120,43700
   > Long-term Liabilities 
10,208
19,393
28,073
33,780
31,827
75,347
129,030
135,022
96,896
386,424
415,308
309,000
194,000
653,000
1,034,000
1,063,000
907,000
330,000
692,000
651,000
1,074,000
0
1,132,000
1,132,00001,074,000651,000692,000330,000907,0001,063,0001,034,000653,000194,000309,000415,308386,42496,896135,022129,03075,34731,82733,78028,07319,39310,208
       Other Liabilities 
0
0
591
416
356
279
695
494
335
249
4,008
1,000
1,000
41,000
292,000
373,000
345,000
223,000
195,000
164,000
111,000
0
0
00111,000164,000195,000223,000345,000373,000292,00041,0001,0001,0004,00824933549469527935641659100
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
468,590
494,156
329,079
0
0
0
0
0
0
0
0000000329,079494,156468,5900000000000000
> Total Stockholder Equity
0
0
142,490
283,881
345,067
418,480
603,209
675,885
743,922
776,575
832,653
1,017,000
1,197,000
1,337,000
2,396,000
1,514,000
1,685,000
2,117,000
2,135,000
2,453,000
2,135,000
0
2,198,000
2,198,00002,135,0002,453,0002,135,0002,117,0001,685,0001,514,0002,396,0001,337,0001,197,0001,017,000832,653776,575743,922675,885603,209418,480345,067283,881142,49000
   Common Stock
0
0
25,269
29,457
29,712
30,229
33,857
34,236
34,525
34,904
35,091
35,000
35,000
35,000
40,000
40,000
40,000
41,000
41,000
42,000
40,000
0
40,000
40,000040,00042,00041,00041,00040,00040,00040,00035,00035,00035,00035,09134,90434,52534,23633,85730,22929,71229,45725,26900
   Retained Earnings 
0
0
82,140
111,023
161,631
215,854
257,798
371,067
409,723
455,544
529,695
712,000
942,000
1,144,000
1,246,000
1,382,000
1,580,000
1,973,000
1,892,000
2,189,000
2,092,000
0
2,158,000
2,158,00002,092,0002,189,0001,892,0001,973,0001,580,0001,382,0001,246,0001,144,000942,000712,000529,695455,544409,723371,067257,798215,854161,631111,02382,14000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
282,000
282,000
282,000
282,000
282,000
0
0
0
0
0000282,000282,000282,000282,000282,00000000000000000
   Treasury Stock00000-1,000-1,000-1,000-1,000-1,000-1,000-3,000-86-2,222-2,220-2,203-1,124000-18700
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
-8,000
-60,000
-123,000
829,000
1,474,000
65,000
103,000
202,000
222,000
3,000
0
0
003,000222,000202,000103,00065,0001,474,000829,000-123,000-60,000-8,00000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,875,000
Cost of Revenue-1,485,000
Gross Profit1,390,0001,390,000
 
Operating Income (+$)
Gross Profit1,390,000
Operating Expense-785,000
Operating Income367,000605,000
 
Operating Expense (+$)
Research Development149,000
Selling General Administrative544,000
Selling And Marketing Expenses0
Operating Expense785,000693,000
 
Net Interest Income (+$)
Interest Income7,000
Interest Expense-90,000
Other Finance Cost-0
Net Interest Income-83,000
 
Pretax Income (+$)
Operating Income367,000
Net Interest Income-83,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)281,000453,000
EBIT - interestExpense = 522,000
279,000
280,000
Interest Expense90,000
Earnings Before Interest and Taxes (EBIT)612,000371,000
Earnings Before Interest and Taxes (EBITDA)871,000
 
After tax Income (+$)
Income Before Tax281,000
Tax Provision-89,000
Net Income From Continuing Ops192,000192,000
Net Income190,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,270,000
Total Other Income/Expenses Net-86,00083,000
 

Technical Analysis of Hikma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hikma. The general trend of Hikma is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hikma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hikma Pharmaceuticals PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,940 < 2,079 < 2,103.

The bearish price targets are: 1,719 > 1,680 > 1,678.

Tweet this
Hikma Pharmaceuticals PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hikma Pharmaceuticals PLC. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hikma Pharmaceuticals PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hikma Pharmaceuticals PLC. The current macd is -23.77802232.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hikma price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hikma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hikma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hikma Pharmaceuticals PLC Daily Moving Average Convergence/Divergence (MACD) ChartHikma Pharmaceuticals PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hikma Pharmaceuticals PLC. The current adx is 19.01.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Hikma shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Hikma Pharmaceuticals PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hikma Pharmaceuticals PLC. The current sar is 1,877.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hikma Pharmaceuticals PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hikma Pharmaceuticals PLC. The current rsi is 40.94. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Hikma Pharmaceuticals PLC Daily Relative Strength Index (RSI) ChartHikma Pharmaceuticals PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hikma Pharmaceuticals PLC. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hikma price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Hikma Pharmaceuticals PLC Daily Stochastic Oscillator ChartHikma Pharmaceuticals PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hikma Pharmaceuticals PLC. The current cci is -103.95204033.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Hikma Pharmaceuticals PLC Daily Commodity Channel Index (CCI) ChartHikma Pharmaceuticals PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hikma Pharmaceuticals PLC. The current cmo is -22.94673633.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hikma Pharmaceuticals PLC Daily Chande Momentum Oscillator (CMO) ChartHikma Pharmaceuticals PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hikma Pharmaceuticals PLC. The current willr is -83.70786517.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Hikma Pharmaceuticals PLC Daily Williams %R ChartHikma Pharmaceuticals PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hikma Pharmaceuticals PLC. The current atr is 40.09.

Hikma Pharmaceuticals PLC Daily Average True Range (ATR) ChartHikma Pharmaceuticals PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hikma Pharmaceuticals PLC. The current obv is 6,803,563.

Hikma Pharmaceuticals PLC Daily On-Balance Volume (OBV) ChartHikma Pharmaceuticals PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hikma Pharmaceuticals PLC. The current mfi is 36.05.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hikma Pharmaceuticals PLC Daily Money Flow Index (MFI) ChartHikma Pharmaceuticals PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hikma Pharmaceuticals PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Hikma Pharmaceuticals PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hikma Pharmaceuticals PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.943
Ma 20Greater thanMa 501,846.975
Ma 50Greater thanMa 1001,875.418
Ma 100Greater thanMa 2001,833.697
OpenGreater thanClose1,792.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hikma with someone you think should read this too:
  • Are you bullish or bearish on Hikma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hikma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hikma Pharmaceuticals PLC

I send you an email if I find something interesting about Hikma Pharmaceuticals PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Hikma Pharmaceuticals PLC.

Receive notifications about Hikma Pharmaceuticals PLC in your mailbox!